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Abstract
Background: Control programs have been executed in an attempt to reduce vertical transmission and the severity
of congenital infection in regions with a high incidence of toxoplasmosis in pregnant women. We aimed to
evaluate whether treatment of pregnant women with spiramycin associated with a lack of monitoring for
toxoplasmosis seroconversion affects the prognosis of patients.
Methods: We performed a prospective cohort study with 246 newborns (NB) at risk for congenital toxoplasmosis in
Goiânia (Brazil) between October 2003 and October 2011. We analyzed the efficacy of maternal treatment with
spiramycin.
Results: A total of 40.7% (66/162) of the neonates were born seriously infected. Vertical transmission associated
with reactivation during pregnancy occurred in 5.5% (9/162) of the NB, with one showing severe infection
(systemic). The presence of specific immunoglobulins (fetal IgM and NB IgA) suggested the worst prognosis.
Treatment of pregnant women by spiramycin resulted in reduced vertical transmission. When infected pregnant
women did not undergo proper treatment, the risk of severe infection (neural-optical) in NB was significantly increased.
Fetal IgM was associated with ocular impairment in 48.0% (12/25) of the fetuses and neonatal IgA-specific was related
to the neuro-ophthalmologic and systemic forms of the disease. When acute toxoplasmosis was identified in
the postpartum period, a lack of monitoring of seronegative pregnant women resulted in a higher risk of severe
congenital infection.
Conclusion: Treatment of pregnant women with spiramycin reduces the possibility of transmission of infection
to the fetus. However, a lack of proper treatment is associated with the onset of the neural-optical form of
congenital infection. Primary preventive measures should be increased for all pregnant women during the prenatal
period and secondary prophylaxis through surveillance of seroconversion in seronegative pregnant woman should be
introduced to reduce the severity of congenital infection in the environment.
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Background
Congenital toxoplasmosis adversely affects the eye, hear-
ing, and brain function [1-16]. In Brazil, this fact was
unknown until 2010, when mandatory reporting was im-
plemented requiring the assessment of a program to
control for congenital toxoplasmosis throughout this
country [17]. Goiânia, the capital of Goiás, is located in
the central-western region of Brazil. Goiânia has a high
prevalence of toxoplasmosis in women of reproductive
age (65.8%) [18]. Moreover, pregnant women in Goiânia
have one of the highest serological conversion rates in
the world (8.6%) [19], which represents a predisposition
to congenital toxoplasmosis. This situation occurs be-
cause seronegative pregnant women undergoing im-
munological changes, which are typical of pregnancy
[20], and those living in a location with a high preva-
lence of the disease, are more likely to acquire the
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infection [18,19]. This epidemiological risk stimulated
the establishment of a state program to control congeni-
tal toxoplasmosis in October 2003. This program was
linked to another pregnant woman care program created
to help prevention of vertical transmission through pri-
mary and secondary prophylactic measures. These pro-
grams were created in an attempt to reduce vertical
transmission and the severity of congenital infection.
Analyzing a screening programs’ effectiveness is essen-
tial for decision-making in public health politics. Sero-
prevalence data in pregnant women showed a decrease
during the last 30 years in many European Countries, re-
sponsible for the discontinuation of some state programs
control [21]. However, this has not happened in Brazil
due to do the maintenance of the risk factors for acquir-
ing this protozoal infection: low sanitation, feeding
habits, contact with cats, contact with contamined soil,
drinking beverages prepares unboiled water, consump-
tion of municipal or uncontrolled water [18,19,22] and
T. gondii virulence [15]. The infection during pregnancy
is of concern for the consequences that may result in
the fetus and this is of great. Even in an environment
with a low incidence of infection, toxoplasmosis has
proved to be important [23]. Countries that do not per-
form a prenatal control program for congenital toxoplas-
mosis have a higher frequency of severe forms of
congenital infection [24-26]. Large European studies
have questioned the effectiveness of preventive treat-
ment of maternal infections in pregnancy [11,14,27-37].
Furthermore, prophylactic strategies against toxoplasmo-
sis adopted by different public health systems are not al-
ways homogeneous [14,21,23,38-59]; they differ even
within the same country. There is a high prevalence of
toxoplasmosis in France where monitoring of serocon-
version is performed monthly [14,45]. In most control
programs toxoplasmosis in pregnancy surveillance sero-
conversion is held every three months (in three quar-
ters), as in Austria [44] and Italy [50]. A program of
prenatal screening was implemented in Slovenia [46]
and Poland [53], countries with a low incidence of toxo-
plasmosis. And in other countries such as Denmark the
screening program was discontinued [21]. In the United
States [24] and United Kingdom [25,26], congenital toxo-
plasmosis is a rare condition. Therefore, these countries
have not conducted any program for serological screening.
There has been much discussion concerning the signifi-
cance of these government programs to control toxoplas-
mosis in pregnancy [11,14,16,21,23,26,29,32-59]. Several
facts hinder the enforcement of these protocols: identify-
ing the acute phase of infection in pregnancy is difficult
when seroconversion is not performed; proper interpret-
ation of results of an IgG avidity test is difficult to achieve
if it is carried out after 16 weeks of pregnancy [60-62];
treatment-compliance problems; inappropriate assistance
to newborns (NB) according to the reference service; treat-
ment provided for pregnant patients does not prevent ver-
tical transmission of protozoan infection [11,14,16,27-40];
and the type of drug used to treat infected women causes
international controversy [2,5-7,11,14,16,21,23,27-59].
Therefore, this study aimed to assess whether treat-
ment of mothers for acute toxoplasmosis and a lack of
surveillance of serological conversion in seronegative
pregnant women affects their prognosis.
Methods
The population
We performed a prospective cohort study in 246 NB at
risk of congenital toxoplasmosis, conducted between
October 2003 and October 2011 at the Clinical Hospital
(HC), Federal University of Goiás (UFG). This institution
is a reference service for the control of congenital toxo-
plasmosis in Goiás, along with the Mother and Child
Hospital of Goiania (HMI), and outpatient in Associ-
ation of Parents and Friends of Exceptional Children
(APAE). This study was conducted only with the chil-
dren referred to the service reference HC/UFG. The HC
is located in Goiânia. NB of women with specific IgM
against T. gondii and low avidity IgG identified in the
first serological examination prenatally and in NB of
seronegative pregnant women who did not undergo
monitoring for seroconversion during pregnancy were
considered at risk for toxoplasmosis.
Mothers were selected by the Pregnancy Protection
Program in the state of Goiás (PPGGO). These mothers
were referred to the prenatal service at HC/UFG to con-
tinue the treatment initiated with spiramycin throughout
pregnancy, once the presence of IgM in the peripheral
blood of pregnant women, independent confirmation of
fetal infection. But the HC/UFG also meets the demand
of spontaneous pregnancy, which provided an opportun-
ity surveillance of seroconversion in seronegative preg-
nant women seen at their prenatal service (low and high
risk). HC in the seronegative pregnant women con-
ducted surveillance of seroconversion for toxoplasmosis,
repeat serologic testing in the second and third quarters.
In the other services prenatal was not performed surveil-
lance of seroconversion for toxoplasmosis among preg-
nant women at risk for toxoplasmosis. These patients
were followed up until they gave birth at the maternity
ward at HC/UFG. After birth, their NB were subjected
to additional tests to determine the presence of congeni-
tal toxoplasmosis, according to the protocol 039/2002
approved by the Ethics Committee of the HC/UFG for
Human and Animal Research.
NB were selected by: (1) routine postnatal screening in
cord blood for detection of specific IgG and IgM anti-
bodies against T. gondii; (2) postnatal screening (specific
IgMs detected by the Guthrie test) in blood collected on
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filter paper from the digital pulp of NB between the 5th
and 7th days of life - the sample was analyze by paper-
based enzyme-linked immunosorbent assay (ELISA) with
a sensitivity of approximately 100.0%, carried out at the
Association of Parents and Friends of Exceptional Children
(APAE) Goiânia and Anápolis; and (3) serological screen-
ing of peripheral blood of infants suspected congenital in-
fection who were born at other public maternity hospitals
that participate in the PPGGO. Routine postnatal screening
was performed in NB who were born at the maternity ward
of HC/UFG, and their mothers had specific IgM anti-T.
gondii identified prenatally (by a screening test or sero-
logical monitoring). For serological screening, mothers
were diagnosed with acute infection even though they
had shown serological and/or clinical signs of congeni-
tal toxoplasmosis.
The detection of anti-T. gondii IgG and IgM in cord
blood of NB suspected of congenital toxoplasmosis
(mothers with specific IgMs or were seronegative who
did not undergo surveillance of seroconversion pre-
natally) is routinely performed at the maternity ward of
HC/UFG. The specific antibodies were confirmed in per-
ipheral blood of NB and their mothers and were then
compared. By seroconversion, this procedure identified
women who had acute toxoplasmosis in pregnancy but
were not diagnosed in the prenatal period.
Medical and animal research ethics committee approval
The study was approved by the Human and Animal
Experimentation Ethics Committee of the CH at the
UFG (protocol no. 092/2001). Mothers of NB who
agreed to participate signed a free informed term of con-
sent after they have been made aware of the importance
of the research. The protocol for diagnosis of congenital
infection and treatment was approved by the Medical
and Animal Research Ethics Committee from CH/UFG
(039/2002).
Inclusion criteria
Vertical transmission diagnosis was confirmed in NB at
risk of congenital toxoplasmosis whose mothers ac-
cepted to participate in the research. Exclusion criteria
were as follows: (1) mothers who refused to take part in
the research; and (2) inconclusive diagnosis of congenital
infection, and NB whose mothers did not show serocon-
version during pregnancy and who underwent neonatal
screening (46 NB).
PPGGO
This program is responsible for prenatal care for preg-
nant women attending public health services. The med-
ical care in cases of prenatal low risk, is done in the
Health Posts and Health Centers Assistance. In case of
complications during pregnancy (risk pregnancies),
medical care is performed in HC/UFG and Goiânia
HMI. The pregnant women with acute toxoplasmosis
during pregnancy are cared in three reference centers:
HC/UFG, Goiânia HMI and ambulatory APAE. In
addition, a serological survey of other infections that can
be transmitted to the fetus was included in the PPGGO:
syphilis, rubella, cytomegalovirus, human immunodefi-
ciency virus (HIV), hepatitis B and C, human cell lym-
photropic virus (HTLV), and Chagas disease at the time
arrives to perform the pregnant the first prenatal con-
sultation. Women with acute infection had a serological
test for toxoplasmosis, which was performed on filter
paper collected from blood from the digital pulp at the
first time in the prenatal monitoring. Pregnant patients
were considered to have an acute infection when a spe-
cific IgM was confirmed and the avidity of IgG (<30%)
was low. Tests were performed before 16 weeks of preg-
nancy. These criteria were also used by Lapplainnen M
et al. [60], Jenum et al. [61], and Werblin et al. [62].
Acutely infected patients were treated with spiramycin
3 g/day (from diagnosis to delivery), regardless of fetal
infection or may not be present. When the patients
started the prenatal monitoring after 16 weeks of preg-
nancy and the presence of specific IgM anti-T. gondii
antibodies was confirmed, they underwent treatment be-
cause identifying the acute phase of protozoal infection
was not possible. The diagnosis of fetal infection was
carried out by identification of T. gondii by the follow-
ing: (1) polymerase chain reaction (PCR) or isolation of
T. gondii from mice; and (2) the presence of specific
IgM antibodies in amniotic fluid and/or fetal blood from
biological material collected after the 20th week of gesta-
tion by amniocentesis and cordocentesis, respectively.
The procedures was performed by a specialist in fetal
medicine.
Congenital Toxoplasmosis Control Program (CTCP)
NB who met the criteria were included in the CTCP,
which took place in the HC/UFG. In the HC/UFG, NB
suspected of congenital infection were subjected to labora-
tory tests and routine procedures for the diagnosis of con-
genital infection, according to the service approved by the
Ethics Committee of the CH/UFG (039/2002).
The CTCP considers a patient infected when: (1) T.
gondii is isolated from peripheral blood or cerebrospinal
fluid (CSF) by experimental inoculation in mice or DNA
analysis with PCR; (2) specific anti-T. gondii IgM and/or
IgA in fetal or NB blood is identified; (3) specific anti-
bodies (IgG and/or IgM) are found in the CSF of NB; (4)
the specific IgG (NB) is larger (4×) than maternal IgG;
(5) NB IgG-specific antibody levels increase or remain
positive after 12 months of life; and (6) a clinical alter-
ation is compatible with the congenital infection in the
absence of other diagnoses (Chagas disease, syphilis,
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rubella, cytomegalovirus, HIV, HTLV, and hepatitis B
and C). The specific IgM and IgA were confirmed with a
new blood sample collected between the 5th and 10th
day of life. Fundus examination of the eye was per-
formed at the Reference Center of Ophthalmology
(CEROF), at the Department of Ophthalmology, Faculty
of Medicine of UFG.
NB infected or suspected of being infected were
treated according to the protocol approved by the Ethics
Committee of the CH/UFG (039/2002). Treatment con-
sisted of sulfadiazine (100–150 mg/kg/day) four times a
day (every 6 hours), pyrimethamine (1–2 mg/kg/day)
twice a day (every 12 hours), and folinic acid orally
given in a daily dose of 3.5 mg. When protein levels in
the CSF were >150 mg/dl or when there was acute oph-
thalmological impairment, a daily dose of prednisone
(2–3 mg/kg/day) was added to the treatment. Drug
doses were adapted to the neonatal period: sulfadiazine
(100–150 mg/kg/day), twice daily in the first week of
life; pyrimethamine (1–2 mg/kg/day) three times per
week for 28 days. These conditions were maintained
until there was certainty of no vertical transmission.
However, for the infected patients, the duration of
treatment depended on the presence of clinical abnor-
malities at birth (2 years) or on the absence of clinical
signs (1 year).
Laboratory techniques
Screening in pregnant women performed at the Institute of
Diagnostic and Prevention (IDP) in the APAE in Goiânia
For the identification of specific anti-T. gondii in the
blood of pregnant women, blood samples were collected
by finger prick on filter paper S&S 903, according to
standard procedures of the IDP in the APAE in Goiânia.
Serological screening for toxoplasmosis in the eluate of
filter paper was performed through ELISA kits, regis-
tered at the Ministry of Health by the National Agency
for Sanitary Surveillance. The sensitivity of the filter
paper technique for the identification of IgM anti-T.
gondii was 99.8% [63] and the serum sensitivity was
97.9% (determined by the manufacturer). A similar study
conducted in pregnant women from Mato Grosso do
Sul state, in the mid-west of Brazil, found an IgM sensi-
tivity in filter paper of 99.4% [64]. This test was repeated
in the peripheral blood of pregnant women and con-
firmed by ELISA kits registered at the National Agency
for Sanitary Surveillance. An IgG avidity test (before 16
weeks of gestation) was performed to determine if acute
infection occurred before pregnancy (with high avidity).
A low avidity test was considered as indicative of acute
infection, as described in other studies [60-62].
Analysis of blood using the filter paper technique was
described by Minuzzi [63]. Briefly, 3 μl of serum was
used for the extraction of the IgM anti-T. gondii
antibody, and this was placed in 200 μl of elution. The
plate was homogenized at 1000 × g at room temperature
for 1 hour and the tests were accomplished using an au-
tomated ELISA analyzer. The antibody capture method
was based on ELISA. The presence of specific anti-IgM
T. gondii allows the conjugated connect to the solid
phase through the presence of toxoplasma antigen. The
enzyme activity is proportional to the concentration of
specific IgM present in the samples or controls. The en-
zymatic activity was analyzed by adding a colorless solu-
tion of chromogen/substrate, and was measured with a
photometer. For measurement of enzymatic activity,
100 μl of calibrator and controls were added to the cor-
responding wells of a plate. Blood spots on filter paper
(strip-sensitized) were eluted with 200 μl of the eluent.
The plate was incubated for 60 minutes at 37°C and
washed with washing buffer five times. A total of 100 μl
of conjugate was dispersed in each well, and the plate
was incubated for 60 minutes at 37°C. The plate was
washed again with washing buffer five times. A volume
of 100 μl of conjugate was placed in each well, and the
plate was incubated for 30 minutes at room temperature
protected from light. A volume of 100 μl of blocking so-
lution was then added to each well and gently mixed for
30 seconds. The plate was then immediately read at
450 nm on a microplate reader.
Techniques used for the neonatal diagnosis of congenital
toxoplasmosis
The following tests were performed at the Laboratory of
Immunology HC/UFG (serology) and Laboratory Studies
of the Host-Parasite Relationship (LAERPH) of the Insti-
tute of Tropical Pathology and Public Health (IPTSP) at
UFG. These tests were used as markers of congenital in-
fection with T. gondii. Serological tests to determine the
presence of specific anti-T. gondii IgM and IgA anti-
bodies were performed. Parasitological identification
tests, such as experimental inoculation in mice and/or
PCR to analyze biological samples suspected of being
contaminated (fetal blood, amniotic fluid, blood, and
CSF of NB) were also performed.
Parasitological examination Blood samples were col-
lected before specific medication was given to NB. These
samples were taken to determine the presence of a para-
site by PCR or experimental inoculation in mice (using ac-
cording to Silva et al. [65]. PCR was performed according
to the following protocol. DNA was extracted according
to specifications from the Pure Link Genomic Purification
kit for purification of genomic DNA (Invitrogen). The
PCR reactions were performed in the MasterCycler per-
sonal thermocycler. The amplification process consisted
of initial denaturation at 94°C (5 min), 35 cycles of de-
naturation at 94°C (1 min), annealing at 62°C (1 min), and
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extension at 72°C (1 min), followed by a final extension at
72°C (10 min). The PCR reactions were performed in du-
plicate, using a sequence of the B1 gene of T. gondii. The
following primers were used: Toxo-B5 (5′-TGA AGA
GAG GAA ACA GGT GGT CG-3′) and Toxo-B6 (5′-
CCG CCT CCT TCG TCC GTC GTA-3′). The PCR
products were visualized by 6% polyacrylamide gel elec-
trophoresis and the gel was stained using silver nitrate
[66]. Peritoneal fluid from mice infected with the T. gondii
RH strain was used as a positive control.
Serological tests Serological tests were used to detect
anti-T. gondii IgG and IgM in blood samples of NB.
Neonatal serological screening was performed using the
indirect fluorescent antibody test (IFAT), according to
Camargo et al. [67,68], and the microparticle enzyme
immunoassay (MEIA). The IgM detection test for sus-
pected patients of congenital toxoplasmosis was per-
formed using the three techniques of IFAT, MEIA, and
enzyme-linked fluorescent assay (ELFA). Methodologies
used for detection of anti-T. gondii-specific antibodies
were followed according to the manufacturer’s instruc-
tions. The specificity for IgM of the tests was 100.0%,
except for IFAT-IgM, which was 91.7%. The sensitivity
of the tests was 60.9% for MEIA-IgM, 60.9% for ELFA-
IgM, 59.6% for IFAT-IgM, and 57.1% for ELISA-IgA (as
described in Rodrigues IMX et al.), [69].
The IFAT technique was used according to Camargo
et al. [67,68], with Biolab conjugate (Fluoline G and M).
The presence of IgM was demonstrated by removal of
rheumatoid factor, using reagents produced by Biomérieux.
The reference values for IFAT were as follows: nonreac-
tive, <1/10; and reactive, ≥1/10.
MEIA was used for the quantitative determination of
anti-T. gondii IgG and IgM antibodies in the CSF (NB)
or in the plasma of the pregnant women, NB, and puer-
peral patients. The MEIA was performed by following
the instruction manual for the AXsYM ABBOTT im-
munochemical automated analyzer. Reference values
for IgG were as follows: reactive, >3 UI/mL; indeter-
minate, 2–3 UI/mL; and nonreactive, <2 UI/mL. Refer-
ence values for IgM were as follows: reactive, >0.600
UI/mL; indeterminate, 0.500–0.600 UI/mL; and nonre-
active, <0.500 UI/mL.
ELFA was used for the quantitative determination of
anti-T. gondii IgM antibodies in the plasma of NB by fol-
lowing the instruction manual. Reference values for IgM
using ELFA were as follows: nonreactive, <0.55 UI/mL; in-
determinate, >0.55 and < 0.65 UI/mL; and reactive, >0.65
UI/mL (Biomérieux Instruction Manual Toxo-M). The
ELFA was used because it involves immunocapture IgM
antibodies. This process avoids false-positive results be-
cause of the presence of rheumatoid factor, and avoids
false-negative results because of excess IgG, reactions.
This procedure also has a sensitivity and specificity com-
pared with ISAGA, of 93.5% and 99.3%, respectively.
ELISA was used for the determination of IgA, according
to the instruction manual. The specific anti-T. gondii IgA
was examined using double-sandwich ELISA (capture).
Reference values for specific IgA were as follows: nonreac-
tive, <4.5 UA/mL; indeterminate, 4.5–5 UA/mL; and re-
active, >5 UA/mL. Blood samples were sent to a private
laboratory to detect anti-T. gondii IgM using the ELFA
(VIDAS, Biomérieux) and IFAT [60].
Statistical analysis
The data were computerized with Excel 2007 [SPSS 15.0
for Windows] was used for statistical analyses. We ex-
amined whether there was association between each of
the variables. The results were compared with the pres-
ence and absence of maternal treatment with spiramy-
cin. P values < 0.05 were considered as statistically
significant with a 95% confidence interval. Fisher’s exact
test was used when numbers were less than 5. Statistical
calculations excluded cases where there was no informa-
tion on the time of occurrence of the diagnosis of toxo-
plasmosis and maternal treatment.
Results
The Protection Program for Pregnant women in Goiás
made possible the diagnosis of 162 children infected
with T. gondii (Table 1). These children were sent to the
Reference Center in the HC/UFG.
Among the 246 women whose infants were followed
up at the Reference Center for Congenital Infections,
30.1% (74/246) were seronegative at the first prenatal
visit. Seroconversion was identified during gestation in
16.2% (12/74) of women who underwent prenatal care at
the HC/UFG, which conducts monitoring of seroconver-
sion in pregnant patients at risk of infection or seronega-
tive women. Other women were diagnosed by the
identification of specific anti-T. gondii IgG and/or IgM
in the cord blood of NB. This was confirmed by the ana-
lysis of peripheral blood of NB and mothers.
The fetal IgM test was performed in 29.0% (47/162) of
the cases and 53.2% (25/47) were positive. A total of
48.0% (12/25) cases where specific IgM was detected de-
veloped ophthalmological impairment. Neonatal IgM
was positive in 38.5% (62/161) of the cases and neonatal
IgA was positive in 20.4% (18/88). Patients with specific
anti-T. gondii IgA (61.1% [11/18] developed a severe
form of infection. A total of 85.7% (6/7) of the children
with widespread disease were specific for IgA.
The parasite (T. gondii) was identified in 31.7% (38/120)
of children and 34.2% (13/38) had a severe disability.
In addition, CSF was abnormal in 70.9% (78/110) with
T. gondii-specific IgG associated with a nonspecific
condition. In 22 cases of congenital toxoplasmosis
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asymptomatic with abnormal CSF (28.2%), with no
other laboratory markers of congenital infection, the
change CSF helped in the diagnosis. Twelve of these
cases had clinical signs late (6 children had chorioreti-
nitis and 6 manifested seizures). In 13 NB IgG showed
up in bonds much higher than maternal IgG. In the
other 56 cases (71.8%) where changes were observed in
the CSF, there was concomitant presence of other
markers of congenital infection (IgM and/or IgA spe-
cific, and identification of T. gondii by PCR and/or
mouse inoculation.
Among 162 infected patients, 40.7% (66/162) of them
were born seriously sick. Among the seven patients who
showed widespread disease, two also had neurological
and optical impairments (Table 1). Furthermore, 30.8%
(50/162) of the NB were born with ophthalmological im-
pairment and 76.0% (38/50) of those also had neurological
impairment. Among these, 20.0% (10/50) developed only
the optical form, while 4.0% (2/50) had the systemic form
of the disease. In addition, in these children, 52.0% (26/50)
were born with poor eyesight, 50.0% (13/26) of these were
blind, and 50.0% (13/26) had peripheral vision because of
bilateral macular impairment. The systemic form was
found in 4.3% (7/162), 31.5% (51/162) had intracranial cal-
cifications, and among children with neurological damage,
37.2% (19/51) developed hydrocephalus.
There were no cases of systemic forms (Table 2), hear-
ing or lymph nodes, in the third trimester of prenatal
diagnosis. Among 62 seronegative pregnant women who
were not monitored during pregnancy, and who had
acute infection with T. gondii, 87.1% (54/62) had
children infected and 64.8% (35/54) had severe forms of
congenital infection (intracranial calcifications, neural-
optical, ocular or systemic).
Furthermore, 4.9% (8/162) of the patients were in-
fected with toxoplasmosis and cytomegalovirus, and
showed cerebral impairment characteristic of both
infections.
Mortality associated with congenital infection was
4.3% (7/162).
A total of 45% (9/20) of women who had T. gondii in-
fection before pregnancy (months before pregnancy or
previous pregnancy) gave birth to infected children
(Table 3). Four (44.4%) of those children developed an
asymptomatic form of the disease, three (33.3%) had
asymptomatic meningitis, one (11.1%) developed the sys-
temic form of toxoplasmosis, and one (11.1%) had an
ocular form of toxoplasmosis. Six cases of T. gondii in-
fection occurred in previous pregnancies (1 neonatal
death) and the other three occurred 3 months before
pregnancy. No patient was infected by HIV or any other
Table 2 Distribution of vertical transmission during the









n % n %
Before
pregnancy
11 14.1 9 6.0
1st trimester 35 44.9 43 28.5
2nd trimester 18 23.1 24 15.9 < 0.001 1.694
3rd trimester 6 7.7 21 13.9 (1.349 – 2.128)
After birth 8 10.3 54 35.8
Total 78 100.0 151 100.0
Test: Kruskal Wallis.
Table 1 Distribution of clinical forms of congenital
toxoplasmosis according to the type of maternal
diagnosis of toxoplasmosis (2012, Goiânia/GO, Brazil)











1) Asymptomatic 30 (54.6) 14 (25.4) 11 (20.0) 34 (21)
2) Meningitis 26 (76.5) 8 (23.5) 0 (0.0) 11 (6.8)
3) Intracranial
calcifications
8 (72.7) 3 (27.3) 0 (0.0) 38 (23.5)
4) Neural-optical 11 (28.9) 27 (71.1) 0 (0.0) 10 ( 6.2)
5) Ocular 6 (60.0) 4 (40.0) 0 (0.0) 7 (4.3)
6) Systemic 1 (14.3) 6 (85.7) 0 (0.0) 4 (2.4)
7) Auditory 4 (100.0) 0 (0.0) 0 (0.0) 3 (1.8)
8) Nodal 1 (33.3) 2 (66.7) 0 (0.0)
Sub-total 87 (53.7) 64 (39.5) 11 (6.8) 162 (65.8)
Without
toxoplasmosis
68 (80.9) 10 (11.9) 6 (7.2) 84 (34.2)
Total 155 (63.0) 74 (30.1) 17 (6.9) 246 (100.0)
Table 3 Distribution of children by severe forms of
congenital toxoplasmosis by time of gestation at which







N % N % N % N %
Before pregnancy 1 9.1 1 10.0 ― 0.0 1 14.3
1st trimester 5 45.5 1 10.0 7 18.4 ― 0.0
2nd trimester 2 18.2 1 10.0 4 10.5 ― 0.0 0.021
3rd trimester 1 9.1 3 30.0 4 10.5 ― 0.0
After birth 2 18.2 4 40.0 23 60.5 6 85.7
Total 11 100.0 10 100.0 38 100.0 7 100.0
P 0.297 0.406 0.001 0.001
Test: x2.
IC = intracranial calcifications.
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infectious disease (Chagas disease, syphilis, rubella,
CMV, HTLV, and hepatitis B and C).
The use of spiramycin during pregnancy was con-
ducted when the diagnosis of acute infection was estab-
lished for presence of IgM antibodies in the bloodstream
in pregnancy when associated with low avidity IgG
(serological screening was conducted in the first prenatal
visit); and when before pregnancy specific anti-T. gondii
IgM persistence in the bloodstream, or with fetal com-
promise.) Furthermore, spiramycin was also used in the
presence of seroconversion (specific anti-T. gondii IgG
and IgM were identified in women who were previously
seronegative). A total of 120 women were treated
(Table 4). Among these women, 70 NB were born with
congenital toxoplasmosis and 18.6% (13/70) of them
were born severely infected. A total of 115 pregnant
women were not treated. Among these women, 73% NB
(84/115) had congenital infection and 60.7% (51/84) of
them were born severely infected (Table 4). The neural-
optical form of congenital infection occurred in all tri-
mesters of pregnancy (Table 3). However, this form of
infection (neural-optical) occurred in 36.9% (31/84) of
NB of mothers who were not subject to antiparasitic
treatment with spiramycin and it occurred in only 7.1%
(5/70) when they were treated.
Transmission of congenital toxoplasmosis was signifi-
cantly associated with the time of diagnosis of maternal
infection (p = 0,021), Table 3. Maternal diagnosis was as-
sociated with a significant difference as to severe forms
of congenital infection (neuro-optical and systemic), in
relation to the lack of diagnosis of maternal infection.
The lack of diagnosis of maternal infection favored sig-
nificantly congenital transmission of toxoplasmosis
(Table 3).
41 pregnant women who had a diagnosis of toxoplas-
mosis during pregnancy did the indicated treatment. Of
these, 26 had children infected and in 15 of them the
children were not infected with T. gondii. Lack of treat-
ment of pregnant women with spiramycin was signifi-
cantly associated with the appearance of vertical
transmission and a severe form of congenital infection
(neural-optical) (Table 4). And the treatment of pregnant
women decreased the incidence of severe fetal infection.
Discussion
Although follow-up for serological conversion is recom-
mended with a high prevalence of infection [12,14,
23,42-47,60,70,71], this was not performed in the pro-
gram state control of toxoplasmosis in Goiânia. Preg-
nancy increases the chances for infection to take place
[72], especially in locations with a high prevalence of
infection and major environmental contamination
[22], contact with animal reservoirs, poor dietary
habits, and low levels of formal education [18]. These
conditions are experienced by pregnant women par-
ticipating in prenatal services in public health
throughout Brazil [18,19,22,72].
In our study, the diagnosis of congenital disease was
difficult to establish [73,74]. Mothers suffered from acute
toxoplasmosis or a recurrent form of the disease because
of the low sensitivity of congenital infection markers. In
NB, diagnostic markers of congenital toxoplasmosis
showed a low sensitivity (IgM specific, 38.5%; IgA spe-
cific, 20.4%; and identification of T. gondii, 31.7%),
smaller than that found by Bessieres et al. in 2009 [75],
64% (IgM) and 53% (IgA) Gilbert et al., [76], 52% (IgM)
and 55% (IgA) and Pinon et al. [77], of 56.7%, in relation
to serological markers. However, are similar to results ob-
tained by Carvalheiro et al. [78] in Ribeirão Preto, Brazil.
Also smaller to findings by Bessieres et al. [79] compared
with identification of the parasite (61%). The identification
of diagnostic markers of congenital toxoplasmosis differs
Table 4 Distribution of children by occurrence of
congenital toxoplasmosis according to maternal
treatment with spiramycin during pregnancy
(2012, Goiânia/ GO, Brazil)
Aspects Maternal treatment p OR (IC)
Treated Untreated
N % N %
1) Clinical type
Mild form birth 57 81.4 33 39.3 0.148
Severe disease at birth 13 18.6 51 60.7 <0.001 (0.070-0.311)





50 41.7 31 27.0 0.018 0.517
Congenital
toxoplasmosis
70 58.3 84 73.0 (0.298-0.895)
Total 120 100.0 115 100.0




5 38.5 6 11.8
Ocular 2 15.4 8 15.7
Neuro-optical 5 38.5 31 60.8 0.030 0.377
Systemica 1 7.7 6 11.8 (0.185-0.765)
Total 13 100.0 51 100.0
4) Mild form birth
Assimptomatic 32 56.1 19 57.6
Meningitis 20 35.1 12 36.4 0.321 1.222
Nodal 1 1.8 2 6.1 (0.678-2.201)
Auditory 4 7.0 0 0.0
Total 57 100.0 33 100.0
Test: x2.
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depending on the treatment used during pregnancy.
Couvreur et al. [71] identified the parasite in 42% of cases
when used in association with pyrimethamine and sulfa-
diazine and 76% when using the spiramycin. In this study,
IgM was also less identified among neonates whose
mothers received sulfadiazine + pyrimethamine (17.4%)
than among children of women who received spiramycin
(69.2%). Bessières et al. in 2001 [79] also analyzed the ef-
fect of medication provided to pregnant women with
acute toxoplasmosis according to the results of diagnostic
markers of congenital infection. They also found reduc-
tion in the identification of the parasite in cord blood
when the women were treated with pyrimethamine and
sulfadiazine compared with little interference when spira-
mycin was used. Our findings of decreased transmission
of severe forms of toxoplasmosis using only the spiramy-
cin may be due to the fact that the strain of congenital
toxoplasmosis in the Midwest region of Brazil (Goiânia) is
more sensitive to spiramycin than the strain present in
Europe.
These results imply that this type of infection should
be further investigated, even though there is inter-
national debate on the subject that PCR performed on
amniotic fluid is more important than other tests
[80-85]. Foulon et al. [81] identified the T gondii in am-
niotic fluid in 81% of cases of toxoplasmosis; Bessieres
et al. [79] identified of the parasite in placenta (60%) or
umbilical cord blood (43%). Moroever, Knerer et al. [81],
could not identify the importance of PCR in amniotic
fluid.
Therefore, fetal-specific IgM proved to be a better
marker for congenital infection than the peripheral
blood NB test (53.2% and 38.5%, respectively). Found
higher than those described by Foulon et al. [80] for spe-
cific IgM anti-T. gondii fetal (43%). However fetal-
specific IgM can be considered a poor marker because it
failed to be useful to diagnose nearly half of the infected
patients. An important finding is that 48.0% of fetuses
who presented with IgM in their bloodstream were born
with ocular impairment. This finding has not been previ-
ously reported in the literature. In the current study,
IgA-specific antibodies anti-T gondii were associated
with the worst prognosis of vertical transmission
(neural-optical and systemic forms), described also by
Rodrigues et al. [69]. The specificity of tests was 100.0%,
except for the IFAT-IgM (91.7%), but this was higher
than that observed by Pinon et al. [77]. In other re-
search, the meeting of specific IgA anti-T. gondii showed
higher sensitivity, as Bessieres et al. (52%) [79] and
Olariu et al. (43,9%) [24].
CSF is abnormal in 70.9% of infected patients and CSF
is considered an important marker of congenital infec-
tion [5,7]. In our study, 28.2% (22/78) cases of congenital
toxoplasmosis assyntomatical year born (with no other
markers of congenital infection), changes in CSF helped
in early diagnosis of congenital toxoplasmosis. Twelve of
these cases had clinical signs late (6 had chorioretinitis
and 6 manifested seizures). According to Alford [85]
changes in CSF suggest neurological disease severity.
However, Wallon et al. [86] found no significant associ-
ation of CSF for the diagnosis of congenital toxoplasmo-
sis in the neonatal period.
In our study, 5.5% (9/162) of congenital infection af-
fected children of women immunocompetent who had
acute infection prior to pregnancy. The majority of cases
of vertical transmission in acute toxoplasmosis during
pregnancy occur when maternal infection precedes ges-
tation by several months [87-90]. In the current study,
only three out of nine cases would fit that description,
whereas the other six cases occurred in previous preg-
nancies. In addition, two children were born with severe
infection. One of these children had the systemic form
(his mother was diagnosed with acute toxoplasmosis
earlier in pregnancy), and another child was born with
the ocular form of the disease (the mother had acute
toxoplasmosis 3 months before pregnancy). This finding
suggests that this situation likely resulted from a reduced
cellular response of the host during the gestational
period [19]. This situation can interfere with the parasite
load and with the clinical course of maternal infection,
and consequently increase the risk of vertical transmis-
sion. Some authors have reported that IgG-positive preg-
nant women cannot transmit toxoplasmosis, except in
rare cases of acute toxoplasmosis relapse due to im-
munodeficiency of the patient [5,7]. They showed that
toxoplasmosis is a complex infection during pregnancy.
Additionally, even the presence of prior immunity does
not prevent the transmission of infection to the fetus.
Furthermore, severe forms of vertical transmission were
also found in these women in our study. This finding
supports the establishment of preventive measures of a
primary nature (in all pregnant women) to avoid contact
with T. gondii by avoiding potentially contaminated food
(meat, eggs, milk, and raw vegetables), contact with animals
(cats and dogs), and land of gardens [4,5,7,37,58,91,92].
This because Elbez-Rubinstein [89] confirmed that ac-
quired immunity against European Toxoplasma strains
may not protect against reinfection by atypical strains.
Neurological manifestations, including asymptomatic
meningitis, occurred in 52.5% (85/162) (Table 1), and
60% (51/85) of these children developed intracranial
calcification, where 37.2% (19/51) had hydrocephalus.
These results are also similar to those by Desmonts and
Couvreur [2] in France and Safádi et al. (54%] in Brazil
[93]. Furthermore, are larger than those found by Soares
et al. [94] of 32%, also in Brazil. But much higher than
that reported by Peyron et al. [13] of 11.8%; Foulon et al.
[11], of 13% of sequels and Ricci et al. [36], of 31.6%.
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Our results that 40.7% (66/162) of NB were severely af-
fected (Table 1) are better than those found by Olariu
et al. [24], of 84% (when pregnant women and children
were not treated). Gras et al. [16], showed that the treat-
ment made the first 4 weeks of seroconversion reduced
the risk of intracranial calcifications, but that was mean-
ingless if started after that time, but did not affect the
appearance of eye injuries.
Unidentified children at birth showed evolution of the
congenital forms of the disease after birth, which is simi-
lar to results found in the classic studies of congenital
infection [1,5,7]. Notably, these severe forms of congeni-
tal infections occurred more frequently when there was
no diagnosis of acute infection in pregnant women. This
finding can be explained by either a lack of serological
surveillance of conversion in seronegative pregnant
women or an absence of prenatal care. But in our state,
we have a preventive program in pregnant women
should have modified the severity of congenital infec-
tion. However, there were shortcomings in preventive
measures both primary and secondary, which were asso-
ciated with more aggressive strain of T. gondii circulat-
ing among us [15,95].
In the current study, among children with ocular im-
pairment, 52.0% (26/50) were born with poor eyesight,
and one half of them were blind and the other half had
peripheral vision because of bilateral macular impair-
ment. These results are in accordance with Peyron et al.
[13], found that 58.8% of ocular lesions and 12.7% with
low vision and a study by Gilbert et al. [15], who found
more intense aggressiveness of toxoplasmosis in Brazil
than in Europe. Moreover 4.3% (7/162) of children died
as a result of severe congenital infection, similar to that
found by Desmonts and Couvreur [2].
In our study, maternal treatment with spiramycin pre-
vented the neural-optical form of the infection and a
lack of treatment during pregnancy resulted in a greater
risk for this alteration to occur (Table 4), results found
in the different Gras et al. [16] without interference from
the eye injury treatment. In Brazil, it has been observed
that the severity of ocular toxoplasmosis than in other lo-
cations [15,95]. The findings of our study on the ocular
are similar to that found by Peyron et al. [13], of 58.8%,
but the severity of visual impairment was higher (52%)
than the 12.7% found in the study of Peyron et al. [13],
and lower than the 92.2% reported by Olariu et al. [24].
Congenital infection in general was also more severe
because 4.3% (7/162) of children were born with the dis-
seminated form of the disease, and two of these also had
the neuro-optical form of the disease. The disseminated
form of toxoplasmosis has been reported in other stud-
ies [96,97] and currently has been related to the strain II
of T. gondii [96]. A high prevalence of the disseminated
form was found in our study, which is considerably
higher than that found in other countries. In studies car-
ried out in Europe, complications, such as neonatal
death and the systemic form, were reported, but the in-
cidence did not exceed 1.0% of children [11]. Moreover,
4.9% (8/162) of children were infected by both toxoplas-
mosis and cytomegalovirus. Cerebral impairment is a
characteristic of both infections and it made the progno-
sis of the infected patients even worse. These results are
similar to previous studies classic congenital toxoplas-
mosis already published in the literature [1,2,5,7] and in
locations that do not have a control state program for
congenital toxoplasmosis [24,25]. The severity of clinical
toxoplasmosis in Brazilian children may be associated
with the genetic characteristics of T. gondii isolates pre-
vailling in animals a humans in Brazil [22].
When patients were treated with spiramycin during
pregnancy in our study, there was protection against this
severe form of congenital infection and a decrease in fre-
quency from 7.1% (6/84) to 1.4% (1/70). These results
also suggest that there is a major flaw in the current
toxoplasmosis control program of Goiás. The levels of
severity of congenital infection need to be improved by
implementation of primary prophylaxis in all pregnant
women (seronegative and seropositive). Conduction of
surveillance of seroconversion in pregnant women using
serological tests performed on a monthly basis is also re-
quired to control congenital infection and identify ma-
ternal infection at an early stages of the infection. This
would reduce transmission and the severe forms of con-
genital infection.
Hearing impairment was observed in 2.4% of infected
children (Table 1). This finding was transient and disap-
peared with specific antiparasitic treatment in NB. Hearing
changes were also found in other studies [5,98].
Our study found that a lack of monitoring of serocon-
version in 62 pregnant women at risk during the 8 years
of the PCTC in Goiania resulted in 56.4% (35/62) of
children with severe forms of the infection (neurological,
ocular and/or systemic). This number of children is
much higher than that described by Desmonts and
Couvreur [2] and Foulon et al. [11], and where there is
no governmental program for controlling infection avail-
able [29,30]. This finding highlights the need for sero-
logical surveillance of pregnant women, as already
previously recognized [5,7,14,37,50-59,91,92].
In our study, transmission of toxoplasmosis was higher
when acute infection was identified postpartum and not
during pregnancy. This is possibly related to the lack of
maternal treatment. In surveys conducted in Europe,
when acute infection occurred in the third trimester, no
ocular or intracranial impairment was found in NB [51].
In contrast to our study results, no systemic, hearing, or
lymph node impairment was found when the infection
occurred in the third trimester of pregnancy. Moreover,
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neuro-optical forms found in all trimesters of pregnancy
were present in 36.9% (31/84) of children when their
mothers were not subjected to antiparasitic treatment
with spiramycin during pregnancy. Only 7.1% (5/70) of
children showed complications. Therefore, maternal
treatment with spiramycin protected NB against neuro-
optical impairment. A lack of treatment of acutely in-
fected pregnant women also resulted in an increased risk
of developing this type complication (Table 4). This se-
vere form of congenital infection can manifest early at
birth, as shown by the aggressive strain of T. gondii cir-
culating in this study’s region of focus [15,96]. In addition,
maternal treatment decreased the prevalence of these se-
vere forms of toxoplasmosis from 60.7% (51/84) to 18.6%
(13/70). These findings are much higher than those de-
scribed by Schmidt et al. [21]. Previous studies have con-
firmed the importance of treatment of pregnant women
with acute toxoplasmosis, even with spiramycin as a single
drug [5,7,70]. Other studies favor the use of spiramycin in
the first 16 weeks of pregnancy, followed by the associ-
ation of pyrimethamine and sulfadiazine until delivery
[14,27-36,39,42-47,50-59].
In our study, neurological and ocular aggressiveness,
even in children of treated pregnant women, was greater
than that found in areas lacking prenatal preventive pro-
grams. This indicates the need for future research, and
isolation and genetic characterization of the circulating
strains in Goiás, as well as the need for immune assays
of neonates exposed to T. gondii in pregnancy.
In our study, although treatment of spiramycin was ad-
ministered, there was clinical improvement of congenital
infection consequences (sequelae). Moreover, Gras et al.
[16] found no evidence that prenatal treatment with
pyrimethamine-sulphadiazine was more effective than
spiramycin in reducing the risks of intracranial or ocular
lesions in congenitally infected infants.
However, these results with treatment are still higher
than those found in the absence of treatment in other
locations. Schimidt et al. [21] also found higher ocular
aggressiveness among untreated women (9.6%) than in
those who underwent treatment (2.8%).
Determination of specific anti-T. gondii IgM indicated
in the new proposal of the Ministry of Health for pre-
natal programs in public health (Project Stork) is inad-
equate and ineffective based on the results of our study.
This is because this proposal cannot identify seronega-
tive pregnant women (or the risk of development of
acute infection). This identification is important because
the acute infection can only be confirmed as occurring
during pregnancy when seroconversion is identified
[5,7,19,72]. In addition to not performing primary
prophylactic measures, which is effective for decreasing
the rate of acute toxoplasmosis among susceptible
women [5-7,44,46,56,58]. Moreover, treatment of the
early infected fetus is delayed (secondary prevention).
Our study highlights the need for preventive measures
for all pregnant women, especially given that 5.5% of
children who had congenital infection obtained the para-
site from women immune to T. gondii and two of them
developed severe forms of the infection (systemic and
ocular).
Previous studies have shown that diagnosis of acute in-
fection during pregnancy and its consequent treatment
can reduce several forms of congenital infections
[4-14,21,23,32,35,41-48,50-54,57-61,80,81,86]. These stud-
ies emphasize the importance of preventive programs of
congenital toxoplasmosis during pregnancy, including sur-
veillance of seroconversion in seronegative pregnant
women. In Brazil, where congenital infections are more
aggressive than elsewhere in the world, a national program
for controlling toxoplasmosis infection during pregnancy
is highly recommended.
Our study has also indicated the need for improve-
ment in the current program implemented in the state
of Goiás. Primary and secondary prophylaxis measures
should be intensified (e.g., serological surveillance in
seronegative pregnant women and changes in the treat-
ment of acutely infected patients). Monthly serological
screening is suggested, such as the French program for
control of congenital toxoplasmosis [14]. Notably,
money spent on tertiary prophylaxis for severely infected
NB and maintenance of life without quality exceeds what
would be spent to carry out monthly serological tests in
seronegative pregnant women (34.2%). According to
Remington et al. [5], the expense is approximately one
million dollars per patient with a severe form of con-
genital toxoplasmosis.
The treatment of pregnant women is a controversial
issue. That’s because there are no controlled studies on
the efficacy of the medication, but in absence of evi-
dence of prenatal treatment effect does not exclude a
clinically important beneficial effect. Our study is in ac-
cordance with studies that have shown a reduction in se-
verity of fetal infection when the mother was treated
during pregnancy [12,23,34-36,41-47,50-54,57-59]. Also
showed that congenital toxoplasmosis is more severe in
Goiânia than elsewhere [19]. Congenital toxoplasmosis
occurs at much higher levels than in other locations that
do not have a program of prenatal care. Implementation
of primary preventive measures to control infection with
T. gondii is recommended. These measures must be per-
formed regardless of the patient’s immune status against
toxoplasmosis to (1) implement monthly monitoring of
seroconversion for seronegative pregnant women or for
patients at risk, and (2) replace spiramycin by sulfadiazine
after the 20th week of pregnancy (75 mg/kg/day in the first
2 days, followed by 50 mg/day in two doses) and give folinic
acid (10–20 mg/day) until 1 week after withdrawal of
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drugs (up to the moment of birth). This treatment
should be performed even without a diagnosis of fetal im-
pairment because the diagnosis of congenital infections is
complex and the aggressiveness of the infection in Brazil
is severe. Notably, a positive test does not prevent vertical
transmission.
Conclusions
Treatment of pregnant women with spiramycin de-
creases the possibility of transmission of infection to the
fetus. A lack of treatment is associated with the onset of
the neuro-optical form of congenital infection. The oc-
currence of severe forms in pregnant women whose
chronic infection is recurrent demonstrates the need to
expand the primary prophylactic program to all preg-
nant women, regardless of their immune state against T.
gondii. Occurrence of a severe form of congenital infec-
tion remains important in Brazil, despite government
programs. The severity of congenital infection in Brazil
suggests the requirement for secondary prophylaxis pro-
grams with drugs to treat the fetus and pregnant women
who are acutely infected.
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